A 15-year-old boy experienced myoclonic seizures for 3 years. He initially had occasional myoclonus, gradually progressive ataxia, tremors, and psychomotor and speech regression developed. Eventually, he exhibited nearly continuous myoclonus.
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Introduction
Progressive myoclonic epilepsies (PMEs) constitute a group of rare disorders characterized by the development of relentlessly progressive myoclonus, tonic-clonic seizures, and neurological deterioration. Sialidosis, a rare cause of PMEs, is an autosomal recessive disorder resulting from the alpha-N-acetyl neuraminidase deficiency caused by a mutation in the neuraminidase 1 gene located on 6p21.33.
Clinically, sialidosis is of two types. Sialidosis type I is a relatively mild form of the disease, which usually occurs in the second decade of life; it is also known as the cherry-red spot-myoclonus syndrome. Depending on the age of onset, sialidosis type II can be classified into infantile and juvenile forms. In addition to cherry-red spots and myoclonus, patients with sialidosis type II exhibit somatic involvement including coarse face, corneal clouding, and dysostosis multiplex. Until now, no specific treatment has been established for sialidosis. Treatment for sialidosis is limited to symptom relief and supportive care. Myoclonic seizures are often resistant to anti-seizure medication [1] .
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Case report
We report the case of a 15-year-old boy who experienced frequent myoclonic seizures and ataxia for 3 years. He had normal neuropsychiatric development before the initial onset of seizures at the age of 12 years. He presented with generalized and focal myoclonic seizures. Progressive ataxia and psychomotor and speech regression developed 6 months later. The myoclonic seizures were refractory to multiple antiepileptic drugs (AEDs) including clobazam, sodium valproate, levetiracetam, and phenobarbital in full dosage. Furthermore, he had dysarthria and poor feeding, which necessitated nasogastric tube feeding. He was completely bedridden for several months. When he was admitted to our hospital at the age of 15 years and 9 months, he had nearly continuous focal facial myoclonus, which subsequently spread to the extremities. The facial myoclonus lasted for 15-20 seconds and occurred more than After admission, the patient had a partial myoclonic status, which was resistant to many anti-seizure medications and also did not respond to a ketogenic diet. The previous IQ data were available for this patient before the disease onset.
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Discussion
This is the first report describing the efficacy of perampanel as adjunctive therapy for sialidosis, to our knowledge. PMEs constitute a group of disorders characterized by myoclonic seizure, tonic-clonic seizure, and progressive neurological deterioration, which typically occur with cerebellar signs and dementia. A correct diagnosis always helps patients and their families to understand and accept the disease, even if it is incurable [2] . In our patient, evaluations were performed to identify the etiology of PMEs. A survey for aminoacidopathy and mitochondrial disease, as well as a biopsy of the axillary skin yielded negative results. The results of genetic studies for identifying mutations in genes associated with PMEs, such as those in EPM2A, EPM2B, and CSTB, were also negative. The diagnosis of sialidosis type 1 was made based on the clinical pictures and positive NEU1 expression. A longitudinal study of Taiwanese patients with sialidosis type 1 also showed the presence of the c.544A>G mutation in NEU1 in all 17 patients [3] . One patient exhibited a heterozygous mutation resulting in a stop codon [3] .
The treatment of myoclonus and seizures in PMEs is difficult because both tend to be refractory and resistant to commonly used AEDs [4] . For the management of myoclonus, combinations of valproic acid, benzodiazepines, phenobarbital, piracetam,
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zonisamide, and levetiracetam may be used; however, they are not always effective.
Our patient had been treated using most of the anticonvulsants that could be used for treating PMEs; however, the efficacy was unsatisfactory. Finally, the administration of perampanel resulted in the remission of the seizures, inhibition of neurological deterioration, and improvement of quality of life.
Perampanel has been shown to be effective for seizure control in PMEs such as Lafora disease [5] [6] [7] , Unverricht-Lundborg disease [8] , and dentatorubralpallidoluysian atrophy [9] . Furthermore, a report indicated the efficacy of perampanel therapy for a chronic type of posthypoxic myoclonus and Lance-Adams syndrome [10] . Our case demonstrated that perampanel therapy is also effective for sialidosis.
However, the mechanism underlying the antimyoclonic effect of perampanel remains unclear. Perampanel is a noncompetitive, selective α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptor antagonist. AMPA receptors may play a pivotal role in the pathophysiology of epilepsy. The receptors may be involved not only in the occurrence of seizures but also in the progression of epilepsy.
Thus, perampanel is prescribed as adjunctive therapy for primary GTCs and partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy and myoclonus [11, 12] . The mechanism underlying the efficacy of perampanel in sialidosis might involve blocking of the AMPA receptors to normalize the balance of inhibitory and excitatory neurotransmitters in the cortex and cerebellum.
In conclusion, our experience suggests that perampanel is a candidate of choice for treating PMEs such as sialidosis, and we hypothesize that more satisfactory outcomes may be achieved if perampanel is prescribed at the early stage of the disease rather than at a later stage. Additional confirmatory reports may suggest specific drug efficacy of perampanel in the management of PME including sialidosis. 
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Highlights • A case of sialidosis type I with compound heterozygous mutations of c.544A>G and c.619C>T in NEU1 gene was presented with refractory seizures.
• Seizure activities reduced markedly and finally subsided with adjunctive perampanel therapy as titrated to 10 mg/day in the case of sialidosis type I.
• Progressive myoclonic epilepsy (PME) due to sialidosis is mostly drug-resistant to many anti-seizure medications.
• Perampanel might be a potentially effective treatment for sialidosis and other forms of PME. 
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